Enanta Pharmaceuticals Inc Financials
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Enanta Pharmaceuticals Inc has an operating margin of -130.7%, meaning the company retains $-131 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -179.9% the prior year.
Enanta Pharmaceuticals Inc's revenue declined 3.4% year-over-year, from $67.6M to $65.3M. This contraction results in a growth score of 19/100.
Enanta Pharmaceuticals Inc has elevated debt relative to equity (D/E of 3.34), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.
With a current ratio of 4.21, Enanta Pharmaceuticals Inc holds $4.21 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Enanta Pharmaceuticals Inc generated -$19.3M in operating cash flow, capex of $12.9M consumed most of it, leaving -$32.2M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Enanta Pharmaceuticals Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Enanta Pharmaceuticals Inc generates $0.24 in operating cash flow (-$19.3M OCF vs -$81.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Enanta Pharmaceuticals Inc earns $-11.1 in operating income for every $1 of interest expense (-$85.3M vs $7.7M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
This page shows Enanta Pharmaceuticals Inc (ENTA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Enanta Pharmaceuticals Inc generated $65.3M in revenue in fiscal year 2025. This represents a decrease of 3.4% from the prior year.
Enanta Pharmaceuticals Inc's EBITDA was -$80.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 32.3% from the prior year.
Enanta Pharmaceuticals Inc generated -$32.2M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 66.7% from the prior year.
Enanta Pharmaceuticals Inc reported -$81.9M in net income in fiscal year 2025. This represents an increase of 29.4% from the prior year.
Enanta Pharmaceuticals Inc earned $-3.84 per diluted share (EPS) in fiscal year 2025. This represents an increase of 29.9% from the prior year.
Enanta Pharmaceuticals Inc held $32.3M in cash against $0 in long-term debt as of fiscal year 2025.
Enanta Pharmaceuticals Inc had 29M shares outstanding in fiscal year 2025. This represents an increase of 36.2% from the prior year.
Enanta Pharmaceuticals Inc's operating margin was -130.7% in fiscal year 2025, reflecting core business profitability. This is up 49.3 percentage points from the prior year.
Enanta Pharmaceuticals Inc's net profit margin was -125.4% in fiscal year 2025, showing the share of revenue converted to profit. This is up 46.2 percentage points from the prior year.
Enanta Pharmaceuticals Inc invested $106.7M in research and development in fiscal year 2025. This represents a decrease of 18.8% from the prior year.
Enanta Pharmaceuticals Inc invested $12.9M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 28.1% from the prior year.
ENTA Income Statement
| Metric | Q1'26 | Q1'25 | Q3'25 | Q2'25 | Q1'24 | Q3'24 | Q2'24 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $19K-99.9% | $18.6M+1.6% | $18.3M+22.7% | $14.9M-12.0% | $17.0M-5.6% | $18.0M+5.4% | $17.1M-5.3% | $18.0M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $21K-99.9% | $20.9M-23.3% | $27.2M-3.0% | $28.1M+1.5% | $27.7M-3.8% | $28.7M-19.2% | $35.6M-2.2% | $36.4M |
| SG&A Expenses | $9K-99.9% | $9.0M-9.9% | $10.0M-12.2% | $11.4M-11.3% | $12.8M-4.2% | $13.4M-5.8% | $14.2M-13.8% | $16.5M |
| Operating Income | $11K+100.1% | -$11.3M+40.4% | -$18.9M+23.0% | -$24.5M-4.2% | -$23.5M+2.7% | -$24.2M+26.2% | -$32.8M+6.1% | -$34.9M |
| Interest Expense | $3K-99.9% | $3.1M+90.5% | $1.6M-5.6% | $1.7M-12.6% | $2.0M-16.7% | $2.4M-8.1% | $2.6M-25.5% | $3.4M |
| Income Tax | $24-99.9% | $24K-17.2% | $29K+102.2% | -$1.3M-213.7% | -$416K-5.3% | -$395K-8.8% | -$363K+41.6% | -$622K |
| Net Income | $12K+100.1% | -$11.9M+34.6% | -$18.3M+19.4% | -$22.6M-1.6% | -$22.3M+1.6% | -$22.7M+27.3% | -$31.2M+6.7% | -$33.4M |
| EPS (Diluted) | $0.42+200.0% | $-0.42+50.6% | $-0.85+19.8% | $-1.06-1.0% | $-1.05+1.9% | $-1.07+27.2% | $-1.47+7.0% | $-1.58 |
ENTA Balance Sheet
| Metric | Q1'26 | Q1'25 | Q3'25 | Q2'25 | Q1'24 | Q3'24 | Q2'24 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $330K-99.9% | $329.5M+9.5% | $301.0M-6.8% | $323.0M-7.4% | $348.6M-7.4% | $376.7M-8.9% | $413.6M-3.5% | $428.5M |
| Current Assets | $199K-99.9% | $198.7M-10.8% | $222.7M-8.3% | $242.9M-9.4% | $268.1M-10.6% | $299.9M-14.6% | $351.0M-10.1% | $390.3M |
| Cash & Equivalents | $37K-99.9% | $37.4M-16.5% | $44.8M-25.6% | $60.2M-28.6% | $84.3M+126.5% | $37.2M-41.4% | $63.5M+59.1% | $39.9M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $8K-99.9% | $8.5M+1.9% | $8.3M+22.7% | $6.8M-12.0% | $7.7M+16.1% | $6.6M-14.3% | $7.8M-5.1% | $8.2M |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $203K-99.9% | $202.9M-8.5% | $221.8M-3.4% | $229.5M-3.1% | $236.8M-4.4% | $247.8M+0.2% | $247.4M+4.6% | $236.6M |
| Current Liabilities | $45K-99.9% | $44.7M+0.4% | $44.5M-3.0% | $45.9M-6.3% | $49.0M-14.7% | $57.5M+5.4% | $54.6M-12.5% | $62.4M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $127K-99.9% | $126.6M+59.7% | $79.3M-15.2% | $93.5M-16.3% | $111.8M-13.2% | $128.8M-22.5% | $166.1M-13.4% | $191.9M |
| Retained Earnings | $417K+100.1% | -$416.9M-7.9% | -$386.2M-5.0% | -$368.0M-6.6% | -$345.3M-6.9% | -$323.0M-19.0% | -$271.6M-13.0% | -$240.4M |
ENTA Cash Flow Statement
| Metric | Q1'26 | Q1'25 | Q3'25 | Q2'25 | Q1'24 | Q3'24 | Q2'24 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $12K+100.1% | -$11.7M-166.8% | $17.5M+229.8% | -$13.5M+19.7% | -$16.8M-61.5% | -$10.4M+63.6% | -$28.6M-14.5% | -$25.0M |
| Capital Expenditures | $143-99.9% | $143K-7.7% | $155K-93.9% | $2.5M-71.0% | $8.7M-2.3% | $9.0M+436.6% | $1.7M+111.9% | $787K |
| Free Cash Flow | $12K+100.1% | -$11.8M-168.2% | $17.4M+208.3% | -$16.0M+37.3% | -$25.5M-32.0% | -$19.4M+36.1% | -$30.3M-17.4% | -$25.8M |
| Investing Cash Flow | $47K+100.1% | -$47.3M-78.6% | -$26.5M-506.2% | -$4.4M-106.3% | $68.9M+261.3% | $19.1M-67.5% | $58.6M+546.9% | -$13.1M |
| Financing Cash Flow | $64K-99.9% | $64.1M+1098.4% | -$6.4M+6.7% | -$6.9M-38.1% | -$5.0M+30.9% | -$7.2M-12.5% | -$6.4M+12.7% | -$7.3M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ENTA Financial Ratios
| Metric | Q1'26 | Q1'25 | Q3'25 | Q2'25 | Q1'24 | Q3'24 | Q2'24 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | 60.5%+120.9pp | -60.5%+42.7pp | -103.2%+61.2pp | -164.3%-25.5pp | -138.8%-4.2pp | -134.6%+57.5pp | -192.1%+1.6pp | -193.8% |
| Net Margin | 64.1%+128.3pp | -64.1%+35.6pp | -99.7%+52.0pp | -151.7%-20.3pp | -131.4%-5.4pp | -126.1%+56.6pp | -182.7%+2.9pp | -185.6% |
| Return on Equity | 9.4% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | 3.6%+7.2pp | -3.6%+2.4pp | -6.1%+0.9pp | -7.0%-0.6pp | -6.4%-0.7pp | -5.7%+1.9pp | -7.5%+0.3pp | -7.8% |
| Current Ratio | 4.440.0 | 4.44-0.6 | 5.00-0.3 | 5.29-0.2 | 5.47+0.3 | 5.21-1.2 | 6.43+0.2 | 6.25 |
| Debt-to-Equity | 1.600.0 | 1.60-1.2 | 2.80+0.3 | 2.45+0.3 | 2.12+0.2 | 1.92+0.4 | 1.49+0.3 | 1.23 |
| FCF Margin | 62.1%+125.7pp | -63.6%-158.4pp | 94.7%+202.1pp | -107.4%+43.3pp | -150.6%-32.0pp | -118.6%+58.9pp | -177.5%-34.3pp | -143.2% |
Similar Companies
Frequently Asked Questions
What is Enanta Pharmaceuticals Inc's annual revenue?
Enanta Pharmaceuticals Inc (ENTA) reported $65.3M in total revenue for fiscal year 2025. This represents a -3.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Enanta Pharmaceuticals Inc's revenue growing?
Enanta Pharmaceuticals Inc (ENTA) revenue declined by 3.4% year-over-year, from $67.6M to $65.3M in fiscal year 2025.
Is Enanta Pharmaceuticals Inc profitable?
No, Enanta Pharmaceuticals Inc (ENTA) reported a net income of -$81.9M in fiscal year 2025, with a net profit margin of -125.4%.
What is Enanta Pharmaceuticals Inc's earnings per share (EPS)?
Enanta Pharmaceuticals Inc (ENTA) reported diluted earnings per share of $-3.84 for fiscal year 2025. This represents a 29.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Enanta Pharmaceuticals Inc's EBITDA?
Enanta Pharmaceuticals Inc (ENTA) had EBITDA of -$80.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Enanta Pharmaceuticals Inc's operating margin?
Enanta Pharmaceuticals Inc (ENTA) had an operating margin of -130.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Enanta Pharmaceuticals Inc's net profit margin?
Enanta Pharmaceuticals Inc (ENTA) had a net profit margin of -125.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Enanta Pharmaceuticals Inc's free cash flow?
Enanta Pharmaceuticals Inc (ENTA) generated -$32.2M in free cash flow during fiscal year 2025. This represents a 66.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Enanta Pharmaceuticals Inc's operating cash flow?
Enanta Pharmaceuticals Inc (ENTA) generated -$19.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Enanta Pharmaceuticals Inc's total assets?
Enanta Pharmaceuticals Inc (ENTA) had $280.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Enanta Pharmaceuticals Inc's capital expenditures?
Enanta Pharmaceuticals Inc (ENTA) invested $12.9M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Enanta Pharmaceuticals Inc spend on research and development?
Enanta Pharmaceuticals Inc (ENTA) invested $106.7M in research and development during fiscal year 2025.
How many shares does Enanta Pharmaceuticals Inc have outstanding?
Enanta Pharmaceuticals Inc (ENTA) had 29M shares outstanding as of fiscal year 2025.
What is Enanta Pharmaceuticals Inc's current ratio?
Enanta Pharmaceuticals Inc (ENTA) had a current ratio of 4.21 as of fiscal year 2025, which is generally considered healthy.
What is Enanta Pharmaceuticals Inc's debt-to-equity ratio?
Enanta Pharmaceuticals Inc (ENTA) had a debt-to-equity ratio of 3.34 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Enanta Pharmaceuticals Inc's return on assets (ROA)?
Enanta Pharmaceuticals Inc (ENTA) had a return on assets of -29.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Enanta Pharmaceuticals Inc's cash runway?
Based on fiscal year 2025 data, Enanta Pharmaceuticals Inc (ENTA) had $32.3M in cash against an annual operating cash burn of $19.3M. This gives an estimated cash runway of approximately 20 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Enanta Pharmaceuticals Inc's Piotroski F-Score?
Enanta Pharmaceuticals Inc (ENTA) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Enanta Pharmaceuticals Inc's earnings high quality?
Enanta Pharmaceuticals Inc (ENTA) has an earnings quality ratio of 0.24x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Enanta Pharmaceuticals Inc cover its interest payments?
Enanta Pharmaceuticals Inc (ENTA) has an interest coverage ratio of -11.1x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Enanta Pharmaceuticals Inc?
Enanta Pharmaceuticals Inc (ENTA) scores 24 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.